Publication
International arbitration report
In this edition, we focused on the Shanghai International Economic and Trade Arbitration Commission’s (SHIAC) new arbitration rules, which take effect January 1, 2024.
Avoiding legal and regulatory pitfalls in digital transformation projects
Asia | Publication | August 2024
This article first appeared in the September 2024 issue of Financier Worldwide.
Digital transformation projects are prevalent across the globe. According to Statista, worldwide spending on digital transformation technologies and services is projected to reach $2.49 trillion in 2024 and $3.9 trillion by 2027. Most companies are replacing legacy systems and have embraced cloud technologies. The use of generative artificial intelligence (GenAI) solutions, while not as widespread presently, is rising rapidly.
We are seeing numerous cutting-edge transactions involving digital transformation. These projects bring enormous benefits to companies, including improved staff and customer satisfaction, increased operational efficiency, the ability to aggregate and analyse data, and the development of new products and services. At the same time, we have seen an assortment of legal and regulatory issues that frequently arise in these projects. These may range from minor issues that can be settled over a phone call to high-priority matters that can prevent a project from getting off the ground or delivery being disrupted or delayed. In this article, we consider some of the pitfalls that lie in wait for the unwary.
Recent publications
Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .